Glenbrook crosses 30% of SenesTech after buying spree
What's the deal? Glenbrook Capital Management now owns more than 30% of SenesTechDealroom has a profile for this one. Try Dealroom →, the rodent-control company, and has published a letter urging the board to tighten its marketing and curb equity dilution. The firm called SenesTech "grossly undervalued" given its market opportunity.
Why now? The stake increase follows a sustained buying campaign. In May, Glenbrook reported a 19.95% position of 1,057,804 shares, acquired for about $3.6 million; it has since pushed past the 30% mark.
What's the endgame? Glenbrook, a backer since before SenesTech's IPO, wants to end what it calls a "recurring cycle of dilutive offerings and reverse splits." It has retained branding firm Sandstrom Partners at its own expense and is pressing the company to pay staff in equity rather than cash to conserve its balance sheet.
By the numbers: SenesTech posted record second-quarter 2026 revenue of $770,000, and preliminary third-quarter revenue of about $1.1 million, up 55% year over year. But the business is still loss-making, with a $1.8 million net loss in Q2 and $5.1 million in cash at quarter-end.
What could go wrong? The stake is a conviction signal, not proof of stability. Glenbrook's own letter flags the risk its fellow shareholders already know: sales have "lagged the game-changing nature of SenesTech products," and the company remains small and unprofitable.
The signal: A single investor crossing 30% in a micro-cap is a strong bet that operating momentum — Glenbrook cited a $4 million run rate — can finally close the gap between product and sales. For now it is engagement, not control: Glenbrook says it wants to "work cooperatively with the Board and management team" rather than force a change.
Read more: prnewswire.com
Image credit: jpockele
